Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, et al
Using data from over 45 million de-identified patient records, the team found that more than 870,000 people were prescribed a GLP-1RA between 2011 and 2023
Future work should therefore validate key pathways under conditions that better reflect the metabolic context of patients with ASCVD or heart failure
Claessens, M., Saris, W
typically $30-150/month if covered Cash-pay options: $1,200-1,350/month without discounts Semaglutide Costs Brand-name list price: Ozempic: ~$1,000/month Wegovy: ~$1,350/month Manufacturer cash-pay (NovoCare): $349/month for either formulation Compounded semaglutide: $199/month through TrimRx With insurance: Variable
Already, at least 1 in 8 American adults [archived link] have taken a GLP-1 and more than half would qualify to take one, according to the latest estimates [archived link]